Update on IGRA Predictive Value
|
|
- Mitchell Shaw
- 5 years ago
- Views:
Transcription
1 Update on IGRA Predictive Value Sandra Kik, PhD Molebogeng Rangaka, MD, PhD Madhukar Pai, MD, PhD McGill International TB Centre, McGill University University of Cape Town & London School of Hygiene and Trop Med
2 Latent tuberculosis infection (LTBI) Hugh reservoir of people with a latent tuberculosis infection 1/3 rd of the world population is estimated to be infected with M. tuberculosis (approximately 2.3 billion people) Yearly about 8.7 million new tuberculosis cases (2011) 2
3 Simple distinction between LTBI and active TB No infection CONTAC T Infection(LTBI) No disease progression (90%) Early (5%) Progression to active disease Late (5%) = reactivation Estimated 10% of LTBI cases will develop active TB Highest risk of disease progression 2-5 years after infection
4 Diagnostics in use for diagnosis of LTBI Tuberculin skin test (TST) Interferon-gamma release assays (IGRA) QuantiFERON TB Gold In Tube? T-SPOT.TB In house RD1 ELISA or ELISPOT 4
5 Guidelines on IGRAs IGRAs not recommended for diagnosis of active TB Most low incidence countries recommend IGRAs for contact investigation in adults As a single test After a positive TST Or together with TST Denkinger et al. CMI
6 Visits Immune response LTBI vs active disease TST or IGRA? TST or IGRA? Multiple visits needed for TST, single visit for blood draw IGRA Both measure evidence of TB infection. TST likely to remain positive, IGRA more likely to revert over time Both cannot distinguish between LTBI and active disease Sensitivity Similar, in the order of 70-80% Specificity HIV TST low specificity since impacted by previous BCG vaccination IGRA high specificity (~95%) Both are impacted by HIV (less sensitive), but IGRA less so 6
7 Systematic review and meta-analysis published in 2012 New studies have been published since this time 7
8 We are currently updating this systematic review Objectives: Can IGRA predict the development of incident active TB? Is predictive ability of IGRA higher than TST? What is the incidence rate of TB in IGRA+ and IGRA- subjects? What is cumulative risk ratio for pos vs neg IGRA by incorporation bias? What is incidence rate ratio of IGRA+ vs IGRA- by type of IGRA? 8
9 Methods Search was repeated for publications since Jun 2011-Jan 2013, using same terms and in- and exclusion criteria Inclusion criteria: Longitudinal studies (pro/retrospective), at least 1 yr follow-up Adults /children, with/without HIV, without TB at baseline Any IGRA (in house or commercial) with RD1 antigens Reported any incidence of (clinical) TB, no restrictions on how TB was diagnosed Exclusion criteria: Studies that had zero incident TB cases Data extraction: 1 reviewer extracted data, other reviewer verified all data extracted 9
10 Methods: quality assessment Modified Newcastle-Ottawa quality assessment scale for observational studies* Selection of study groups Whether methods to exclude TB included smear and/or culture Comparability of study groups Ascertainment of exposure or outcome Microbiological confirmation of TB outcomes Assessment of whether IGRA results were incorporated into the diagnosis of active TB (incorporation bias) Assessment of whether IGRA+ people where more actively investigated for TB disease than IGRA- people (differential work-up bias) * 10
11 Example of study with high likelihood of incorporation & differential work-up bias 11
12 Work-up bias: Example of study with high likelihood of incorporation & differential work-up bias Incorporation bias: Study staff not blinded to IGRA results 12
13 Example of study with high likelihood of incorporation & differential work-up bias Discussion section of Aichelburg paper, acknowledge possibility of bias: Incorporation bias / work-up bias may lead to: Overestimation of the TB incidence rate in IGRA positives Overestimation of the risk ratio of IGRA positives vs IGRA negatives Overestimation of the incidence rate ratio of IGRA positives vs IGRA negatives 13
14 Overview previous and new studies (N=20) 14
15 Study characteristics of included studies ( new) Study area: 11 High income countries (Austria, Netherlands, Norway, Japan, Germany, Portugal, Korea, UK, France) 5 Middle income countries (Turkey, Colombia, China, India, South Africa) 4 Low income countries (Ethiopia, The Gambia, Senegal, Kenya) Type of study population TB contacts: 10 studies Outpatients: 3x HIV+, 2x other immuno-compromised Other: renal transplant recipients, health care workers, adolescents with no prior TB, asylum seekers, HIV exposed infants IGRA s assessed: ELISPOT: 8* (3x in-house, 5x T-SPOT.TB) WBA: 13* (2x in-house, 11x QFT-GIT) * 1 study assessed both T-SPOT.TB and QFT-GIT 15
16 Study characteristics of included studies ( new) TST assessed: 12/20 All 20 studies used one IGRA at baseline (no repeat testing for conversions) Median follow-up: 3 yr IPT: given to all/some of the study participants in 11/20 16
17 Studies included in our analysis What is the incidence rate of TB in IGRA+ and IGRAsubjects? 12/20 studies What is cumulative risk ratio for pos vs neg IGRA by incorporation bias? 20/20 studies What is incidence rate ratio of IGRA+ vs IGRA- by type of IGRA? 9/20 studies (only those without incorporation bias) 17
18 New New Study ID IGRA positive Hill (2008) Bakir (2008) Kik (2009), WBA Kik (2009), ELISPOT del Corral (2009) Lienhardt (2010) Leung (2010) Jonnalagadda (2010), mothers Jonnalagadda (2010), infants Joshi (2011) Mahomed (2011) Kim-SH (2011) Lange (2012) Kim-Y (2012). IGRA negative Hill (2008) Bakir (2008) Kik (2009), WBA Kik (2009), ELISPOT del Corral (2009) Lienhardt (2010) Leung (2010) Jonnalagadda (2010), mothers Jonnalagadda (2010), infants Joshi (2011) Mahomed (2011) Kim-Y (2012). NOTE: Weights are from random effects analysis TB incidence rates (per 1000) Silicotic men HIV-infected moms and infants HIV-infected outpatients, untreated Incidence Rate (95% CI) 9.24 (3.80, 14.60) (10.00, 36.00) (5.50, 39.00) (7.30, 43.40) 7.70 (5.00, 11.30) (8.40, 23.00) (17.80, 52.30) (15.00, 91.00) (16.00, ) 3.69 (1.66, 8.00) 6.40 (4.50, 8.00) (8.17, 62.10) (0.00, 33.00) (34.00, ) 5.00 (1.90, 8.10) 6.00 (1.60, 15.40) (2.50, 35.00) (1.30, 37.50) 4.00 (1.70, 8.50) 6.90 (2.50, 14.90) 7.10 (0.90, 25.50) (3.00, 47.00) (5.00, 69.00) 3.38 (1.69, 6.76) 2.00 (1.20, 3.80) (11.80, 71.50) 12/20 publications reported TB incidence rates IGRA-positive: Incidence ranges from 0.4 to 8% IGRA-negative: Incidence ranges from 0.2 to 3%
19 New studies New studies Association between IGRA and incident TB: Study ID RR, stratified by potential incorporation/work-up bias None Doherty (2002) Hill (2008) Bakir (2008) Kik (2009) Kik (2009) del Corral (2009) Lienhardt (2010) Leung (2010) Jonnalaggada (2010) Jonnalaggada (2010) Joshi (2011) Kim-SH (2011) Kim-Y (2012) Subtotal (I-squared = 0.0%, p = 0.721). Possible Aichelburg (2009) Yoshiyama (2010) Harstad (2010) Diel (2011) Mahomed (2011) Costa (2011) Haldar (2012) Lange (2012) Bergot (2012) Subtotal (I-squared = 55.2%, p = 0.022). Overall (I-squared = 47.6%, p = 0.007) NOTE: Weights are from random effects analysis Risk Ratio (95% CI) (1.42, 70.22) 1.84 (0.79, 4.31) 3.80 (1.22, 11.86) 1.96 (0.40, 9.53) 1.40 (0.34, 5.74) 1.89 (0.83, 4.34) 2.13 (0.85, 5.34) 3.82 (0.89, 16.40) 2.69 (0.69, 10.52) 2.23 (0.54, 9.12) 1.09 (0.38, 3.10) (0.96, ) 3.32 (1.09, 10.08) 2.29 (1.65, 3.17) (7.16, ) 6.74 (3.63, 12.52) (2.36, ) (9.00, ) 2.89 (1.55, 5.41) (0.99, ) 6.52 (2.54, 16.76) (1.15, ) 3.55 (0.22, 56.48) 9.02 (4.32, 18.84) 3.71 (2.53, 5.43) 20/20 publications reported RR No bias: Overall RR 2.29 ( ) Possible bias: Overall RR 9.02 ( )
20 Association between IGRA and incident TB: IRR, stratified by type of assay (only studies without incorporation bias) Study ID Incidence Rate Ratio (95% CI) New ELISPOT Hill (2008) Bakir (2008) Kik (2009), ELISPOT Lienhardt (2010) Leung (2010) Jonnalagadda (2010), mothers Jonnalagadda (2010), infants Kim-Y (2012) Subtotal (I-squared = 0.0%, p = 0.997). WBA Kik (2009), WBA del Corral (2009) Joshi (2011) Subtotal (I-squared = 0.0%, p = 0.784). Overall (I-squared = 0.0%, p = 0.996) 1.90 (0.80, 4.50) 3.41 (1.08, 10.70) 1.41 (0.32, 7.15) 2.00 (0.84, 5.41) 4.50 (1.03, 19.68) 2.60 (0.70, 10.30) 2.00 (0.40, 13.10) 2.62 (0.76, 9.33) 2.09 (0.94, 3.25) 1.91 (0.41, 13.78) 1.82 (0.80, 4.20) 1.00 (0.31, 3.58) 1.41 (0.25, 2.57) 1.75 (0.93, 2.57) ELISPOT: IRR: 2.09 ( ) WBA: IRR: 1.75 ( ) NOTE: Weights are from random effects analysis
21 IGRA vs TST comparison: which has greater predictive value? (studies that did a head-to-head) None of the new studies qualified to be included in this analysis; thus results of Ranganka et al still hold. 21
22 Incidence rate of discordant results: (studies that did a head-to-head) Incidence rate per 1000 person years Gambia (Hill et al) Turkey (Bakir et al) Senegal (Lienhardt et al) India (Joshi et al) TST+ / IGRA TST+ / IGRA TST- / IGRA TST- / IGRA None of the new studies qualified to be included in this analysis; thus results of Ranganka et al still hold. 22
23 Work in progress Final search to be updated till July We know of at least 2 studies that are expected to be published soon. Secondary analysis still to be performed: Stratification by preventive therapy & HIV-status. 23
24 Conclusions thus far of this update Incidence rates of TB, even in IGRA positive individuals, are low, suggesting that a vast majority (>95%) of IGRA+ individuals do not progress to TB disease during follow-up. This is similar to the TST. Based on the evidence thus far, IGRAs appear to have similar predictive value as the TST (perhaps slightly higher, but statistically not significant). All existing LTBI tests (TST and IGRAs) have only modest predictive value and may not help identify those who are at highest risk of progression to disease. In some settings (mostly low TB incidence), the % IGRA+ will be less than % TST+, reducing the number needed for preventive therapy. 24
25 TST can be positive in all states except the last IGRAs are likely to be positive in all states as well? Or spontaneous convert/revert? Nat Rev Micro
26 Are there ways to increase the predictive value for a LTBI test? 1. Only test those who are at high risk 2. Incorporate biomarkers with other known risk factors (age, recent conversion, HIV etc.) into a composite scoring system to generate multivariable risk prediction models 3. Use a higher cut-off for prediction (as compared to diagnosis) 4. Use serial testing to resolve underlying phenotypes (e.g. stable conversions) 5. Identify new biomarkers and measure an array of biomarkers (biosignature) 26
27 Bottom line IGRAs are an incremental advance; not transformational* We are still looking for a highly predictive LTBI test that can help target preventive therapy We need biomarkers and composite risk prediction models that can help resolve the various phases of LTBI spectrum *LoBue P & Castro K. JAMA
28 Acknowledgement LSHTM / University of Cape Town Lele Rangaka for the hard work/support McGill University Madhukar Pai Dick Menzies
AT HIGH RISK OF PROGRESSING TO ACTIVE TB? Senior Lecturer and Consultant Physician University Hospitals of Leicester UK
HOW WELL DO IGRAS PERFORM IN THE IDENTIFICATION OF PERSONS WHO ARE AT HIGH RISK OF PROGRESSING TO ACTIVE TB? Dr Pranab Haldar MD MRCP Senior Lecturer and Consultant Physician University Hospitals of Leicester
More informationPredictive Value of interferon-gamma release assays for incident active TB disease: A systematic review
Predictive Value of interferon-gamma release assays for incident active TB disease: A systematic review Lele Rangaka University of Cape Town, South Africa mxrangaka@yahoo.co.uk 1 The 3 I s Isoniazid preventive
More informationEvidence on IGRAs in Low & Middle Income Countries. Madhukar Pai, MD, PhD McGill University, Montreal
Evidence on IGRAs in Low & Middle Income Countries Madhukar Pai, MD, PhD McGill University, Montreal Madhukar.pai@mcgill.ca Disclosure No industry/financial conflicts I co-chair the Stop TB Partnership
More informationDiagnosis of tuberculosis
Diagnosis of tuberculosis Madhukar Pai, MD, PhD Assistant Professor, Epidemiology McGill University, Montreal, Canada madhukar.pai@mcgill.ca Global TB Case Detection A major concern 2.6 million new smear
More informationRichard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012
Global l Applications of IGRAs Richard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012 Disclosure I have no personal financial conflicts of I have no personal
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationEvidence-based use of the new diagnostic tools for TB-infection
Evidence-based use of the new diagnostic tools for TB-infection Roland Diel, MD, MPH German Central Committee against Tuberculosis, Germany 20. Tuberkulose-Symposium in Münchenwiler, 24 th March 2011 1
More informationModeling LTBI What are the key issues to consider? Dr Dick Menzies, Montreal Chest Institute, McGill International TB Centre
Modeling LTBI What are the key issues to consider? Dr Dick Menzies, Montreal Chest Institute, McGill International TB Centre Overview The problem Treating active TB does not seem to be enough The solution:
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationThe evolving concept of LTBI diagnosis tests for incipient TB and tests for persistent infection
The evolving concept of LTBI diagnosis tests for incipient TB and tests for persistent infection Frank Cobelens f.cobelens@aighd.org KNCV Tuberculosis Foundation The Hague, Netherlands Amsterdam Institute
More informationUse of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING -
Use of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING - Date and time: 20-21 July 2010, 09:00 18:00 Venue: Salle B, WHO-HQ, Geneva, Switzerland
More informationLTBI conception definitions and relevance for diagnostic products
LTBI conception definitions and relevance for diagnostic products Frank Cobelens Amsterdam Institute for Global Health and Development Amsterdam, Netherlands KNCV Tuberculosis Foundation The Hague, Netherlands
More informationEl futuro del diagnostico de la ITL. en tiempos de crisis. Professor Ajit Lalvani FMedSci Chair of Infectious Diseases
El futuro del diagnostico de la ITL. en tiempos de crisis Taller de TB de Barcelona, Noviembre 2012 Professor Ajit Lalvani FMedSci Chair of Infectious Diseases Department of Respiratory Medicine National
More informationReport on WHO Policy Statements
Report on WHO Policy Statements Christopher Gilpin TB Diagnostics and Laboratory Strengthening Unit Secretariat, Global Laboratory Initiative Stop TB Department, WHO Geneva New Diagnostics Working Group
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationScreening and management of latent TB Infection Gerry Davies
Screening and management of latent TB Infection Gerry Davies Reader in Infection Pharmacology Institutes of Infection and Global Health & Translational Medicine HIV Scientific Meeting Liverpool 21st July
More informationInterferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)
More informationJournal of Infectious Diseases Advance Access published August 2, 2013
Journal of Infectious Diseases Advance Access published August 2, 2013 1 Reversion and Conversion of Interferon-gamma Release Assay Results in HIV-1 Infected Individuals Maximilian C. Aichelburg 1,*, Thomas
More informationGuidance for Identifying Risk Factors for Mycobacterium tuberculosis (MTB) During Evaluation of Potential Living Kidney Donors
Summary and Goals On November 13, 2012, the OPTN/UNOS Board of Directors approved a requirement that all potential living kidney donors undergo evaluation for infection with Mycobacterium tuberculosis
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationDetecting latent tuberculosis using interferon gamma release assays (IGRA)
Detecting latent tuberculosis using interferon gamma release assays (IGRA) American Society for Microbiology June 2017 Edward Desmond, Ph.D., D (ABMM) San Lorenzo, CA Edward Desmond has no financial connections
More informationTesting for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle
Testing for TB Bart Van Berckelaer Territory Manager Benelux Subtitle Agenda TB infection pathway TB immunisation Testing options Pre lab considerations of the whole blood ELISA test The T-SPOT.TB test
More informationThese recommendations will remain in effect until the national shortage of PPD solution has abated.
Maryland Recommendations Regarding the National Shortage of Purified Protein Derivative (PPD) Solution; Attachment to Health Officer Memorandum National Shortages of Tubersol and Aplisol for TB Skin Testing;
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More informationInterpretation of TST & IGRA results. Objectives
Interpretation of TST & IGRA results Randall Reves, MD, MSc Volunteer Clinician Denver Metro TB Program and Division of Infectious Diseases, Department of Medicine University of Colorado Denver Objectives
More informationLTBI-Tuberculin skin test. T-Spot.TB Technology. QuantiFERON -TB Gold In Tube T-SPOT.TB ELISA ELISA
LTBI-Tuberculin skin test QuantiFERON -TB Gold In Tube ELISA PPD ~200 antigens 3 ml blood ESAT-6 TB 7.7 16-24 hour incubation Nil Negative control PHA Positive control Andersen et al Lancet 2000;356:1099-1104
More information2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016
Learning Objectives Tuberculosis Case Discussions: Evaluation for Tuberculosis Infection Melissa C. Overman, DO, MPH, CHES, FAOCOPM Describe appropriate technique for TST placement, reading and interpretation
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationNguyen Van Hung (NTP, Viet Nam)
Technical Consultation Meeting on the Programmatic Management of Latent Tuberculosis Infection 31 August-1 September 2017, Seoul, Republic Korea Adopting new LTBI diagnostics at country level: perspective
More informationInterferon-gamma release assay for treatment monitoring of active tuberculosis
JCM Accepts, published online ahead of print on 21 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02278-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Interferon-gamma
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationEvaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)
Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI) CURTIS FOWLER MPT,PA C ASSISTANT CLINICAL PROFESSOR UNIVERSITY OF THE PACIFIC Learning objectives Recognize the appropriate
More informationLiterature Overview. Health Economics. Experience with QuantiFERON -TB Gold. Cellestis Clinical Guide series
Literature Overview Experience with QuantiFERON -TB Gold Health Economics Cellestis Clinical Guide series 2008 www.cellestis.com This literature overview is intended to provide healthcare professionals
More informationCategory Description / Key Findings Publication
PUBLICATIONS Selected T-SPOT.TB test publications, by area of interest, up to 31 th August 2016. Category Description / Key Findings Publication Background A useful primer on the evolution, administration
More informationThorax Online First, published on December 8, 2009 as /thx
Thorax Online First, published on December 8, 2009 as 10.1136/thx.2009.119677 Title Page Cost effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the Quantiferon-TB gold
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationTB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014
TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014 Catalina Navarro, BSN, RN has the following disclosures to make: No conflict of interests No relevant financial relationships with
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationRESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS
Southeast Asian J Trop Med Public Health RESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS Benjawan Phetsuksiri 1, Somchai
More informationEffect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection
CVI Accepts, published online ahead of print on 3 July 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00290-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Effect of prolonged
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationNorthwestern Polytechnic University
Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions
More informationVariation in T-SPOT.TB spot interpretation between independent observers of different laboratories
8 Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories Willeke P.J. Franken 1, Steven Thijsen 2, Ron Wolterbeek 3, John J.M. Bouwman 2, Hanane el Bannoudi
More informationCHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]
CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey
More informationWhat Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ
What Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ Outline Combination prevention for HIV Approaches to TB prevention Individual Household/key
More informationTB, BCG and other things. Chris Conlon Infectious Diseases Oxford
TB, BCG and other things Chris Conlon Infectious Diseases Oxford Epidemiology Latent TB IGRA BCG >50/100000
More informationNIHR HTA Programme. 09 July 2013
NIHR HTA Programme 09 July 2013 The NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC), based at the University of Southampton, manages evaluation research programmes and activities for the
More informationHow should they be evaluated and what evidence is needed for WHO endorsement?
New predictive tests for the diagnosis of tuberculosis infection How should they be evaluated and what evidence is needed for WHO endorsement? Frank Cobelens KNCV Tuberculosis Foundation The Hague, Netherlands
More informationJeffrey R. Starke, M.D. has the following disclosures to make:
AAP 2018 Red Book Tuberculosis: IGRAs and Treatment of TB Infection Jeffrey R. Starke, M.D. May 31, 2018 AAP 2018 Red Book Childhood Tuberculosis: IGRAs and Treatment of TB Infection May 31, 2018 WEBINAR
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationProgrammatic management of latent TB infection: Global perspective and updates. Haileyesus Getahun, MD, MPH, PhD.
Programmatic management of latent TB infection: Global perspective and updates Haileyesus Getahun, MD, MPH, PhD. What is latent TB infection? A state of persistent immune response to stimulation by Mycobacterium
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationExpanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination
IUATLD North American Region Conference February 24, 2017 Vancouver, BC Expanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination Philip LoBue, MD National Center
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationDiagnostic challenges of active childhood TB in Tanzania. Michala Vaaben Rose, MD, Ph.D Department of Infectious Diseases, Hvidovre
Diagnostic challenges of active childhood TB in Tanzania Michala Vaaben Rose, MD, Ph.D Department of Infectious Diseases, Hvidovre 1 Diagnosis of Childhood Tuberculosis Muheza hospital, TZ Hilleroedhospital.dk
More informationConflict of Interest Disclosures:
Mady Slater, M.D. Stanford University Medical Center Division of Infectious Diseases 04/23/14 WOEMA webinar Conflict of Interest Disclosures: I have no financial relationships with commercial entities
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationThe Direct Comparison of Two Interferon-gamma Release Assays in the Tuberculosis Screening of Japanese Healthcare Workers
ORIGINAL ARTICLE The Direct Comparison of Two Interferon-gamma Release Assays in the Tuberculosis Screening of Japanese Healthcare Workers Masaki Tanabe 1, Akiko Nakamura 1, Akie Arai 1, Daisuke Yamasaki
More informationCUSOM Student Health Immunization Requirements
CUSOM Student Health Immunization Requirements Regulatory and legislative authorities require that students demonstrate immunization, immunity and/or protection from multiple contagious diseases before
More informationDiabetes and Tuberculosis: A Practical Approach to Diagnosis and Treatment
Diabetes and Tuberculosis: A Practical Approach to Diagnosis and Treatment Michael Lauzardo, MD MSc Chief, Division of Infectious Diseases and Global Medicine Director, Southeastern National Tuberculosis
More informationIncidence of occupational latent tuberculosis infection in South African healthcare workers
ORIGINAL ARTICLE TUBERCULOSIS Incidence of occupational latent tuberculosis infection in South African healthcare workers Shahieda Adams 1,2, Rodney Ehrlich 2, Roslynn Baatjies 3, Richard N. van Zyl-Smit
More informationSharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center
TB Infection Diagnostics and Treatment Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention 1 Curry International
More informationLatent Tuberculosis Best Practices
Latent Tuberculosis Best Practices Last Updated September 7, 2016 LTBI Demographics in the US o 13million people in the US with LTBI (estimate) o In 2014, approximately 66% of TB cases in the United States
More informationUsing Interferon Gamma Release Assays for Diagnosis of TB Infection
Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation
More informationCurr Opin Pulm Med 15: ß 2009 Wolters Kluwer Health Lippincott Williams & Wilkins
T-cell interferon-g release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings Keertan Dheda a,b,c, Richard van Zyl Smit a, Motasim Badri a and
More informationQuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients
Jpn. J. Infect. Dis., 70, 502 506, 2017 Original Article QuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients Thana Khawcharoenporn 1 *, Benjawan Phetsuksiri 2, Janisara
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2019 Bob Belknap M.D. Director, Denver Metro TB Program Disclosures No relevant financial relationships Objectives Be able to
More informationRichard N. van Zyl-Smit 1, Rannakoe J. Lehloenya 1,2, Richard Meldau 1, Keertan Dheda 1,3,4. Introduction
Original Article Impact of correcting the lymphocyte count to improve the sensitivity of TB antigen-specific peripheral blood-based quantitative T cell assays (T-SPOT. TB and QFT-GIT) Richard N. van Zyl-Smit
More information결핵노출접촉자감염관리 서울아산병원감염내과 김성한
결핵노출접촉자감염관리 서울아산병원감염내과 김성한 TB incidence (2012) TB incidence South Korea 108 China 73 Taiwan 68 Portucal 26 Japan 19 Spain 14 US 3.6 * unit- per 100,000 population Adapted from WHO Adapted from WHO Emerg
More informationScreening of HIV-Infected Patients with IGRAs for LTBI. Background. Tuberculosis is the most prevalent in the world.
Screening of HIV-Infected Patients with IGRAs for LTBI Kentaro Sakashita, Akira Fujita, Shuji Hatakeyma Stay strong, Japan! Tokyo Metropolitan Tama Medical Center Department of Pulmonary Medicine Background
More informationT-Cell Assays for Tuberculosis Infection: Deriving Cut- Offs for Conversions Using Reproducibility Data
T-Cell Assays for Tuberculosis Infection: Deriving Cut- Offs for Conversions Using Reproducibility Data Anandharaman Veerapathran 1,2, Rajnish Joshi 1,2,3, Kalyan Goswami 1,2, Sandeep Dogra 4, Erica E.
More informationLatent TB Infection (LTBI) Strategies for Detection and Management
Latent TB Infection (LTBI) Strategies for Detection and Management Patrick T. Dowling MD,MPH Professor and Chair Dept of Family Medicine David Geffen School of Medicine at UCLA Pri-Med March 29 2014 Pdowling@mednet.ucla.edu
More informationIMPACT OF TESTS ON DIAGNOSTIC THINKING AND CLINICAL DECISIONS
IMPACT OF TESTS ON DIAGNOSTIC THINKING AND CLINICAL DECISIONS Madhukar Pai, MD, PhD Associate Professor McGill University, Montreal [madhukar.pai@mcgill.ca] Phased evaluation of medical tests: Diagnostic
More informationThe Tip of the Iceberg: Addressing Latent Tuberculosis Infection to Accelerate Tuberculosis Elimination
Four Corners TB and HIV Conference November 3, 2015 Durango, CO The Tip of the Iceberg: Addressing Latent Tuberculosis Infection to Accelerate Tuberculosis Elimination Philip LoBue, MD National Center
More informationPrevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia
RESEARCH ARTICLE Open Access Prevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia Shaharudin Rafiza 1*, Krishna Gopal Rampal 2, Aris Tahir 3 Abstract Background:
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationTuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant
Tuberculosis and Diabetes Mellitus Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Learning Objectives Understand the impact of uncontrolled diabetes mellitus (DM) on TB infection
More informationAPSR RESPIRATORY UPDATES
APSR RESPIRATORY UPDATES Volume 5, Issue 2 Newsletter Date: February 2013 APSR EDUCATION PUBLICATION Inside this issue: Tuberculosis Multidrug-resistant pulmonary tuberculosis treatment regimens and patient
More informationDiagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010
TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 Diagnosis and Medical Case Management of Latent TB Infection Bryan Rock, MD April 27, 2010 DIAGNOSIS AND MANAGEMENT OF LATENT TUBERCULOSIS
More informationLATENT TUBERCULOSIS. Robert F. Tyree, MD
LATENT TUBERCULOSIS Robert F. Tyree, MD 1 YK TB OFFICERS Ron Bowerman Elizabeth Roll Mien Chyi (Pediatrics) Cindi Mondesir (Pediatrics) The new guys: Philip Johnson Robert Tyree 2009 CDC TB CASE DEFINITION
More informationProgrammatic management of LTBI : a two pronged approach for ending the TB epidemic. Haileyesus Getahun Global TB Programme WHO/HQ
Programmatic management of LTBI : a two pronged approach for ending the TB epidemic Haileyesus Getahun Global TB Programme WHO/HQ What is latent TB infection? A state of persistent immune response to stimulation
More informationGenomic signatures of risk of TB disease Tom Scriba, University of Cape Town
Genomic signatures of risk of TB disease Tom Scriba, University of Cape Town 2nd Expert Workshop on the development of tests for progression of LTBI to active disease 1 July 2016 Possible consequences
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
TB Partial Update Appendix 1 - Scope NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial
More informationPredictive value for progression to tuberculosis by IGRA and TST in immigrant contacts
Eur Respir J 2010; 35: 1346 1353 DOI: 10.1183/09031936.00098509 CopyrightßERS 2010 Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts S.V. Kik*,#, W.P.J. Franken ",
More informationTB Diagnostics: Global Market Analysis and Potential
TB Diagnostics: Global Market Analysis and Potential Madhukar Pai, MD, PhD McGill University, Montreal, Canada madhukar.pai@mcgill.ca September 2012 Market analyses are important and necessary To support
More informationAuthor's response to reviews
Author's response to reviews Title: Contribution of Interferon Gamma Release Assays testing to the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Patients: A comparison of QuantiFERON Gold
More informationThe Most Widely Misunderstood Test of All
The Most Widely Misunderstood Test of All Lee B. Reichman, MD, MPH NJMS Global Tuberculosis Institute History of Treatment of Latent Tuberculosis Infection For more than 4 decades, treatment of persons
More informationLTBI: Who to Test & When to Treat
LTBI: Who to Test & When to Treat TB Intensive May 10 th, 2016 David Horne, MD, MPH Harborview Medical Center University of Washington DISCLOSURES I have no disclosures or conflicts of interest to report
More informationWhat is the clinical utility of interferon-γ release assays for the diagnosis of TB in high-tb-burden countries?
REVIEW What is the clinical utility of interferon-γ release assays for the diagnosis of TB in high-tb-burden countries? Peter Daley & Poorvi Chordia Author for correspondence Department of Medicine Unit
More informationMonitoring & evaluation LTBI management in the Netherlands. Key lessons.
Monitoring & evaluation LTBI management in the Netherlands. Key lessons. Gerard de Vries, MD MSc PhD, Coordinator TB control the Netherlands, KNCV Tuberculosis Foundation/RIVM-CIb Global WHO Consultation
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial update) 1.1 Short title Tuberculosis
More informationQFT-Plus: a plus in variability? Evaluation of new generation IGRA in serial testing of students with a migration background in Germany
Knierer et al. Journal of Occupational Medicine and Toxicology (2017) 12:1 DOI 10.1186/s12995-016-0148-z RESEARCH Open Access QFT-Plus: a plus in variability? Evaluation of new generation IGRA in serial
More informationState of the State in TB Control
State of the State in TB Control Jason Stout, MD, MHS Wake County TB Medical Consultant NC TB Medical Director Division of Infectious Diseases, Duke University Medical Center Disclosures-Funding NIH (grant)
More informationUnderstanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN
More information